Angry Biden Rages, Curses Out Reporters

 by Steve Watson via Modernity.news,

Joe Biden viciously snapped at reporters Sunday as they asked him if he still believes President Trump is a threat to Democracy.

Biden was asked about Trump’s plans to end birthright citizenship, and suddenly had a bizarre outburst about his own age.

“Do you still believe he’s a threat to democracy?” a reporter asked.

“I think what he did was a genuine threat to democracy,” Biden answered.

He rambled about immigration, stating “I mean, this has been, it’s who we are, and we are so connected to the rest of the world. Everywhere I go the rest of the world gets it.”

Biden claimed that “When I became president, the numbers came way down,” referring to illegals crossing the border. This is clearly a blatant lie as the number skyrocketed to all time highs.

He also claimed “I pushed very hard for bipartisan agreement to put more people on the border, more, more secret service agent[s], and guess what? [Trump]’s on the phone saying, ‘Don’t do it. Don’t do it, [it will] make me look bad. That bill, that bill is ridiculous. It’s ridiculous.’”

Biden then weirdly raged at reporters “My being the oldest president, I know more world leaders than any one of you have ever met in your whole goddamn life.”

“And I know them. You know how they think? Not a joke,” he further snapped.

Weird flex, but ok.

Maybe he’s referring to the dead world leaders from the 1980s again?

*  *  *

https://www.zerohedge.com/political/watch-angry-biden-rages-curses-out-reporters

Biopharma Heads to JP Morgan Seeking an M&A Spark to Improve Sentiment

 

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

Despite the cautious optimism a year ago, 2024 did not exactly bust the biopharma industry out of the prolonged downturn that followed the pandemic boom. Going into the 2025 J.P. Morgan Healthcare Conference, leaders in the space are a bit more pessimistic.

“Sentiment is really bad in general in biotech,” Seaport Therapeutics CEO Daphne Zohar told BioSpace.

That said, Zohar and others are looking forward to potentially big news that could spark that optimistic attitude once again. The annual gathering in San Francisco is a who’s who of biopharma with thousands of executives descending on the Bay Area looking to strike deals. The meeting, which officially begins next Monday, Jan. 13, sets the tone for the year, and for many executives who spoke to BioSpace, a few high-profile transactions could really change the tune. But, Zohar commented, it needs to happen early.

“If we don’t see a lot of M&A between now and, like, the Tuesday of J.P. Morgan, I think we’ll have kind of negative sentiment,” Zohar said in a late December interview. “I always feel like, by Monday, if you’re not seeing a lot, then people begin to assume that there’s not much that’s going to happen.”

Linda Marbán, CEO of cell and exosome-based therapy biotech Capricor Therapeutics, agreed that the industry will be watching closely. And despite the swirling gloom, some of last year’s “cautious optimism” still exists, she wrote in an email to BioSpace.

“While challenges like clinical failures remind us of the complexity of developing transformative therapies, they also reinforce the importance of innovation and persistence,” she said. “I think everyone is eager to see what opportunities JPM will bring.”

2024: A Lull in Big Deals

2024 ended with multiple high-profile clinical failures: Roche’s Prothena-partnered Parkinson’s drug; Novartis’ similar flop for a UCB asset; Galectin’s stock-crushing metabolic dysfunction-associated steatohepatitis (MASH) miss; Axsome’s mixed Alzheimer’s disease agitation results and many more. 2025 didn’t start off much better, with Neumora Therapeutics reporting the Phase III failure of a much-anticipated major depressive disorder candidate.

Meanwhile, companies have been slashing pipelines and headcounts. Even good news has not been reflecting at the stock market, according to Zohar.

2023 ended with a flurry of deals that defined 2024, including one involving Karuna Therapeutics—a biotech formed from Zohar’s former company, PureTech Health. Bristol Myers Squibb swooped in to pick up the neuroscience biotech for $14 billion in the final weeks of that year, then brought the company’s schizophrenia asset to an FDA approval in September 2024. Peer AbbVie had the opposite luck with a similarly timed buyout of Cerevel Therapeutics. The biotech’s lead asset failed in two Phase II schizophrenia trials in November 2024. AbbVie is hoping to have better luck with other assets from the transaction.

2024, meanwhile, didn’t have a ton of sector-defining deals. Companies kept their buys to under $5 billion with just one exception: Novo Holdings’ $16.5 billion acquisition of contract development and manufacturing organization (CDMO) Catalent.

What 2025 holds for the sector remains to be seen, with all eyes on JPM for potentially the first multi-billion dollar announcement of the year. But while a big acquisition would certainly help jumpstart the industry, some positive regulatory news, clinical data or other “meaningful partnerships” could also help sentiment, Marbán said.

Executive Wish Lists

Executives from Galimedix Therapeutics have a lofty set of goals heading into the meeting. Executive Chairman and co-founder Alexander Gebauer told BioSpace that his team will meet with several investment banks and venture capital firms in preparation for raising a crossover round this year. The company, which focuses on small molecule drugs for serious eye and brain diseases, is planning a U.S. initial public offering in 2026.

The IPO window did not open as expected in 2024, so Galimedix’s crew will have their work cut out for them. But Gebauer is confident.

“The investors have become even more selective,” he said in an email. “I believe that quality will prevail; companies with excellent teams and high-quality programs should be able to get the support they require.”

Zevra Therapeutics’ management will head into JPM with both partnering and acquisitions on their minds as well as investor relations meetings. CEO Neil MacFarlane told BiosSpace that his company has executed several buyouts in the past so he’s looking to meet with companies that may have single assets in need of a larger partner with proven infrastructure. At the same time, Zevra is also seeking partners for its idiopathic hypersomnia program.

Thijs Spoor, CEO of radiopharma biotech Perspective Therapeutics, similarly has a big wish list heading into the meeting. “I usually go into J.P. Morgan with three buckets of requests: One is people that want money from us—and I’m not doing really any of those for this go around—and then there’s people that I want money from, and then there’s people that I want to do a deal with.”

Perspective is in the enviable position of not needing to court investors at this year’s meeting, having raised a cash reserve of $250 million in 2024. Instead, Spoor and his team will focus on getting his company’s name out there and updating its story from the year prior.

Seaport, which just emerged in April of last year, will present at the conference in the private company track, according to Zohar. The executive team will be meeting with investors and pharma companies, as well as taking some time to see old friends and colleagues.

Another big headwind over the industry is the presidential transition. Donald Trump will re-take the presidency on January 20, just after the JPM meeting concludes. Zohar and Gebauer both said that the wait for the new administration has suppressed deal activity.

“The sooner stability can be achieved, the more openness [we’ll see] to invest,” Gebauer said.

Immunic Therapeutics Chief Operating Officer Jason Tardio said the macroeconomic stars are aligning for a year full of deal activity: the cost of capital has come down and interest rates are declining. On the policy front, the incoming Trump administration and Republican-led Congress are expected to ease corporate taxes, regulatory hurdles and drug pricing provisions like the Inflation Reduction Act.

“2025 could see significant megadeals as companies look to fill their growth gaps ahead of the looming loss of exclusivity in 2028,” Tardio said.

Whether the deals come now or later, Zohar is similarly confident that deal activity will return, fueled by Big Pharma. “They really need to fill their pipeline, so at some point they’re going to get pretty aggressive.”

https://www.biospace.com/business/biopharma-heads-to-jp-morgan-seeking-an-m-a-spark-to-improve-sentiment

5 FDA Decisions to Watch in Q1

 

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy for hemophilia A and B.

The FDA ended 2024 with a flurry of year-end decisions, capping off a productive year that saw 55 novel approvals. This list includes several potentially practice-changing drugs, including Bristol Myers Squibb’s Cobenfy, the first new mechanism of action for schizophrenia in over three decades, and Sanofi and Regeneron’s blockbuster therapy Dupixent, which in September 2024 became the first biologic approved for chronic obstructive pulmonary disease.

Last year, the FDA also greenlit the industry’s first-ever treatment for metabolic dysfunction-associated steatohepatitis in Madrigal Pharmaceuticals’ Rezdiffra, and introduced a much-needed alternative anti-amyloid treatment option for Alzheimer’s disease in Eli Lilly’s Kisunla.

The gene therapy space also saw several key approvals in 2024, including Pfizer’s Beqvez, indicated for hemophilia B, and PTC Therapeutics’ Kebilidi, which is used for the treatment of L-amino acid decarboxylase deficiencyand is the first direct-to-brain gene therapy cleared by the FDA.

Looking ahead, the FDA is expected to deliver several key verdicts that could shape the industry—and clinical practice—in profound ways. Here are BioSpace’s five most anticipated regulatory decisions in the first quarter of 2025.

Biogen and Eisai’s Leqembi

Indication: Intravenous maintenance for early Alzheimer’s disease

PDUFA: January 25

Amid a disappointing launch—and equally underwhelming sales—Biogen and Eisai are awaiting an FDA approval for the monthly intravenous maintenance regimen of their Alzheimer’s disease therapy Leqembi (lecanemab). The regulator’s final word is due on January 25.

Leqembi, the first anti-amyloid antibody Alzheimer’s drug to win the FDA’s traditional approval, is currently indicated as an intravenous medication administered once every two weeks in approximately hour-long infusion sessions. Under the proposed monthly regimen, the interval between Leqembi doses can be stretched to one month in patients who complete an initial bi-weekly initiation phase—though the exact duration of Leqembi initiation has yet to be determined, according to Biogen and Eisai.

As per the partners, monthly maintenance is designed to help maintain therapeutic levels of Leqembi in the body in order to suppress toxic protofibrils, which otherwise could result in nerve damage and brain injury even after the clearance of amyloid-beta clumps.

The companies are backing their application with modeling results using data from the Phase IIb Study 201 and its related open-label extension study. The models also include data from the Phase III Clarity AD and its open-label extension phase.

Biogen and Eisai are also advancing a subcutaneous injection formulation of Leqembi. In August 2024, Eisai noted that the partners had initiated a rolling Biologics License Application for injectable Leqembi and expect approval by March 2026.

In its most recent quarterly report in November 2024, Eisai lowered its full fiscal year sales forecast for Leqembi to $280 million from its previous guidance of approximately $370 million. Analysts from various firms said at the time that Leqembi’s U.S. launch so far has been disappointing and fraught with various infrastructure challenges.

Still, demand for Leqembi appears to be strong and growing, with Biogen and Eisai touting around 6,000 patients waiting to be initiated on the anti-amyloid therapy, which could translate to future growth once the companies address infrastructure and administrative challenges.

AstraZeneca and Daiichi Sankyo’s Dato-DXd

Indication: Metastatic, HR-positive, HER2-negative breast cancer

PDUFA: January 29

By January 29, the FDA is expected to have released its decision regarding AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for their antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd), which the partners are proposing for the treatment of a type of breast cancer.

Results are mixed for Dato-DXd. In the Phase III TROPION-Breast01 study—which the companies are using to back the BLA—the investigational ADC lowered the risk of death or disease progression by 37% versus the investigator’s choice of chemotherapy, according to an October 2023 readout. At the time, AstraZeneca and Daiichi Sankyo called this effect “statistically significant and clinically meaningful.”

However, a follow-up data drop in September 2024 showed Dato-DXd was unable to significantly boost overall survival in the study. TROPION-Breast01 enrolled patients with inoperable or metastatic breast cancer whose tumors were HR-positive and either HER2-negative or HER2-low.

As for safety, TROPION-Breast01 found Dato-DXd to be well-tolerated overall, with a better adverse event profile than chemotherapy. The most common grade 3 or higher side effects included neutropenia, fatigue and anemia.

Dato-DXd is an ADC designed to target the TROP2 protein, which is highly expressed in several cancers. This binding affinity allows Dato-DXd to deliver its exatecan derivative payload directly to the target cells, triggering their death.

Aside from breast cancer, AstraZeneca and Daiichi Sankyo are also testing Dato-DXd in non-small cell lung cancer, for which the ADC likewise failed to yield significant overall survival improvements in September 2024.

Vertex’s Suzetrigine

Indication: Moderate-to-severe acute pain

PDUFA: January 30

Vertex Pharmaceuticals is advancing a non-opioid analgesic, dubbed suzetrigine, for the treatment of moderate-to-severe acute pain. The FDA’s verdict is due on January 30.

Suzetrigine is an orally available pain signal inhibitor that selectively targets the NaV1.8 voltage-gated sodium channel, a genetically validated pain target that is typically found on peripheral neurons. NaV1.8 is believed to play a role in sensing pain and transmitting signals back to the central nervous system.

Vertex is backing suzetrigine with two Phase II and three Phase III studies, including the NAVIGATE 1 and NAVIGATE 2 trials, which looked at the analgesic efficacy of the drug candidate in patients who had undergone bunionectomy and abdominoplasty, respectively.

Full data from these two late-stage studies, presented in October 2024 at the annual meeting of the American Society of Anesthesiologists, showed that suzetrigine monotherapy improved pain scores by 48.4 points after a tummy tuck. In patients undergoing the toe procedure, suzetrigine lowered pain scores by 29.3 points. Both treatment effects were statistically significant versus placebo.

At the time of the readout, analysts appeared to be torn over suzetrigine. BMO Capital Markets said that the presentation “reaffirms our confidence in the strength of suzetrigine’s profile in acute pain,” while William Blair noted that while suzetrigine “has a strong argument for inclusion in the market,” its “pricing remains a point of investor contention.”

If approved, suzetrigine will represent the first new drug class for acute pain in more than two decades, according to Vertex.

Alnylam’s Amvuttra

Indication: Transthyretin amyloid cardiomyopathy

PDUFA: March 23

On the heels of BridgeBio’s recently approved Attruby is Alnylam’s Amvuttra, which the Massachusetts-basedbiotech is hoping to expand into transthyretin amyloid cardiomyopathy (ATTR-CM).

Amvuttra, which is currently indicated for polyneuropathy of hereditary transthyretin amyloidosis, is an RNA interference treatment that works by knocking down mutant and wildtype TTR mRNA, leading to an overall decrease in protein levels in the serum. Through this mechanism, Amvuttra also lowers TTR deposits in various organs, including the heart, that would otherwise give rise to the various symptoms of cardiomyopathy, including the stiffening of cardiac walls.

To support its ATTR-CM bid, Alnylam is using data from the Phase III HELIOS-B study, which found that Amvuttra had “favorable effects” on survival, cardiovascular events, functional capacity and quality of life in ATTR-CM patients, according to the biotech’s press announcement of the FDA’s acceptance of its supplemental New Drug Application. A presentation at the 2024 American Heart Association’s Scientific Sessions showed that Amvuttra treatment led to a 28% drop in the composite outcome of all-cause mortality and recurrent cardiovascular events.

The FDA is expected to release its verdict on March 23.

If approved, Amvuttra will be the first RNA interference therapeutic for ATTR-CM, in contrast to BridgeBio’s Attruby and Pfizer’s Vyndaqel and Vyndamax, which are TTR stabilizers.

Sanofi’s Fitusiran

Indication: Hemophilia A or B

PDUFA: March 28

To challenge the increasingly popular gene therapy approach to hemophilia, Sanofi is advancing fitusiran, an investigational small interference RNA therapy. The pharma is seeking approval for fitusiran for the treatment of hemophilia A and B patients, regardless of their inhibitor status. The FDA’s decision is due on March 28.

In support of fitusiran’s FDA bid are data from the ATLAS clinical development program. In April 2023, Sanofi announced publications in The Lancet and The Lancet Hematology touting encouraging late-stage results for the siRNA candidate.

One of these studies, dubbed ATLAS-INH, focused on patients with inhibitors and found that 66% of fitusiran-treated participants hit zero monthly bleeding episodes, as compared with 5% of control counterparts who were given an on-demand bypassing agent. The other trial, named ATLAS A/B, enrolled patients without inhibitors, of whom 51% had zero monthly bleeds after fitusiran treatment, versus 5% of comparators treated with on-demand clotting factors.

Taken together, both studies showed that prophylactic fitusiran could reduce the annualized bleeding rate by 90% versus their respective control arms, according to Sanofi.

If approved, fitusiran will introduce a new modality of treatment to a therapeutic space that is increasingly being addressed with gene therapies. Leading the charge is BioMarin’s Roctavian, which became the first FDA-approved gene therapy for hemophilia A in June 2023. It works by restoring the body’s ability to produce the blood-clotting protein factor VIII.

Pfizer is taking a similar approach to hemophilia A with its investigational gene therapy giroctocogene fitelparvovec. In July, the candidate aced its Phase III trial, maintaining over 5% factor VIII activity in 84% of treated patients at 15 months. In February, the pharma won the FDA’s approval for its hemophilia B gene therapy Beqvez.

https://www.biospace.com/fda/5-fda-decisions-to-watch-in-q1

Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, Viking Top Candidate: Analysts

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered by its strong obesity candidate VK2735 and largely de-risked MASH therapy VK2809.

Analysts are expecting mergers and acquisitions to pick up modestly in 2025—a sign of the industry’s slow recovery from its crash in 2023—with a handful of biotechs emerging as prime purchase picks for their bigger counterparts.

California-based Viking Therapeutics appears to lead the list of promising players that could attract serious M&A dollars from Big Pharma, according to several analysts. In an interview over the weekend, Seeking Alpha’s Terry Chrisomalis pointed to the biotech’s “proven drug development model” and “solid obesity drug pipeline.”

Viking’s pipeline is anchored by its lead candidate VK2735, a dual agonist of the GLP-1 and GIP receptors that it is developing both as a subcutaneous and oral therapy for obesity. In November 2024, the biotech released a Phase I readout for the drug’s pill formulation, touting up to 6.8% placebo-adjusted weight loss after 28 days of daily 100-mg doses. A few months earlier, in February 2024, Viking also unveiled Phase II data for the subcutaneous version of VK2735, highlighting a 14.7% drop in body weight after 13 weeks of treatment with a 15-mg injection.

Viking was scheduled to start a Phase II trial for oral VK2735 before the end of 2024, according to Chrisomalis, but “For a Phase 3 study for the injectable version of VK2735 targeting patients with obesity, it needs to meet with the FDA first to discuss such advancement.”

Aside from obesity, Viking’s pipeline also holds promise in metabolic-dysfunction associated steatohepatitis (MASH)—another hot indication for biopharma. The biotech is advancing VK2809, a selective thyroid hormone beta receptor (TRβ) agonist that showed a “best-in-class profile” at the 75th The Liver Meeting of the American Association for the Study of Liver Diseases in November 2024.

Viking at the time presented Phase IIb data for VK2809, demonstrating a 37% to 55% mean decrease in liver fat in patients with biopsy-confirmed MASH after 52 weeks of follow-up. The response rate for VK2809—defined as at least a 30% drop in liver fat—ran from 64% to 88%.

According to Chrisomalis, VK2809’s TRβ-targeting activity has “the very same mechanism of action” as Madrigal Pharmaceuticals’ Rezdiffra, a treatment that has already been approved by the FDA for MASH. “It is my belief that an acquisition of this alone is a reduced risk event for any Big Pharma company wanting to acquire it,” Chrisomalis said of Viking’s MASH program.

Beyond Viking, Seeking Alpha analyst Edmund Ingham also named Madrigal as a top M&A candidate for 2025, as well as Summit Therapeutics with its potential Keytruda killer ivonescimab, and Sarepta Therapeutics with its Duchenne muscular dystrophy program.

These biotechs are well-positioned to take advantage of the coming year, which pharma analyst firm Evaluate expects will see “an increase in dealmaking,” according to its 2025 preview report published last week.

Many observers anticipate the incoming Trump administration—which is expected to be more hands-off and industry-friendly than the Biden administration—to be “good news” for biopharma, according to Evaluate. Still, “what exactly might transpire at the new Trump administration is unclear,” the firm cautioned. What is certain is the need for many big players to expand and deepen their pipelines.

“This makes an M&A uptick [in 2025] almost inevitable,” Evaluate noted.

https://www.biospace.com/business/higher-biopharma-m-a-activity-almost-inevitable-in-2025-with-viking-as-top-candidate-analysts

Trudeau to announce resignation as early as today

 Prime Minister Justin Trudeau is reportedly expected to resign from his position as early as Monday, according to Canadian media.

The news was first reported by the Globe and Mail on Sunday night, citing three sources. The outlet said that it is unclear when exactly the Liberal Party leader will step down, but a resignation is expected to come before a national caucus meeting on Wednesday.

The news comes as Trudeau's popularity continues to dwindle in Canada, which has a national election planned for Oct. 20 of this year. The country continues to suffer from a housing crisis, a declining per-capita GDP and high inflation, among other issues.

According to Canadian pollster Angus Reid, Trudeau has a disapproval rate of around 68% as of Dec. 24, with a meager 28% of Canadians supporting him.

Canada's Prime Minister Justin Trudeau could announce his resignation as early as Monday, Canadian media reports. (DAVE CHAN/AFP via Getty Images)

The potential resignation would also come after Trudeau, who became prime minister in 2015, braved a difficult few months in politics. In September, he faced a no confidence vote in parliament that later failed, despite efforts from the Conservative Party to remove him from office.

On Dec. 16, Finance Minister Chrystia Freeland announced that she was stepping down from Trudeau's cabinet, dealing a significant blow to the prime minister. In her resignation letter, she claimed that the only "honest and viable path" was to leave the Cabinet.

"For the past number of weeks, you and I have found ourselves at odds about the best path forward for Canada," Freeland, who was previously seen as a Trudeau loyalist, wrote.

"Our country is facing a grave challenge," the letter added. "That means keeping our fiscal powder dry today, so we have the reserves we may need for a coming tariff war."

Later in December, one of Trudeau's key allies, New Democratic Party leader Jagmeet Singh, said that he planned to present a formal motion of no-confidence on Jan. 27.

Canada's Prime Minister Justin Trudeau has been facing dwindling popularity in his country. (DAVE CHAN/AFP via Getty Images)

"No matter who is leading the Liberal Party, this government's time is up. We will put forward a clear motion of non-confidence in the next sitting of the House of Commons," Singh said.

Trudeau's personal choices have also invited backlash from his opponents. At the end of November, Trudeau faced international criticism after he was seen dancing at a Taylor Swift concert in Toronto while a destructive riot took place in his home city of Montreal.

Don Stewart, a Member of Parliament (MP) representing part of Toronto, called out the prime minister in a post on X.

"Lawless protesters run roughshod over Montreal in violent protest. The Prime Minister dances," the Canadian politician wrote. "This is the Canada built by the Liberal government."

"Bring back law and order, safe streets and communities in the Canada we once knew and loved," Stewart added. Trudeau later denounced the lawlessness, calling the riot "appalling."

https://www.foxnews.com/world/canadian-pm-justin-trudeau-announce-resignation-early-monday-report

'Seattle Public Schools See 20% Spike In Student Homelessness After 30% Rise Last Year'

 Seattle Public Schools is seeing an alarming rise in the number of its students experiencing homelessness. 

As of October, the district reported 2,235 students experiencing homelessness since the school year began, a nearly 20% increase from last year’s 30% rise, KUOW/NPR reported. 

Homelessness has reached record levels nationwide, according to a recent HUD report. In Washington state, over 41,000 students experienced homelessness during the 2023-24 school year, a nearly 15% increase.

Jenny Allen, a McKinney-Vento support worker in Seattle, said rising costs and limited affordable housing are straining families, while the district has seen a rise in immigrants and refugees, particularly from South America.

The KUOW/NPR report said that at Dunlap Elementary, Rogers Greene, an eight-year veteran supporting unhoused students, now assists a growing number of families fleeing conflicts in countries like Ukraine and Afghanistan.

"I can't imagine. You're just dropped somewhere and then figure it out — figure out the language, figure out how you're going to live, where you're going to live, how you're going to eat. It's survival. So it's important for us to have those connections, relationships, and work through the language barrier," he said. 

He continued: "They may not know of those services, those resources that they can access, so part of my job is to educate. But what I want to get to with families is a point of empowerment — like they've accessed a resource, they've used it successfully, they know of some organization where they've been helped, and they can share that with someone else or another family."

Greene supports immigrant and refugee families facing language barriers and fear of seeking help, the report said. 

At Dunlap Elementary, he provides essentials like coats and backpacks, supervises lunches, and creates a safe space for students. Unhoused students face significant academic challenges, but Greene highlights their resilience, noting how many quickly adapt and thrive.

https://www.zerohedge.com/markets/seattle-public-schools-sees-alarming-20-spike-student-homelessness-after-30-rise-last-year